Public Employees Retirement System of Ohio Takes Position in Keros Therapeutics, Inc. $KROS

Public Employees Retirement System of Ohio acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) in the second quarter, Holdings Channel.com reports. The fund acquired 50,324 shares of the company’s stock, valued at approximately $538,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd increased its position in Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after buying an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of Keros Therapeutics during the second quarter worth about $90,000. PDT Partners LLC purchased a new stake in shares of Keros Therapeutics during the second quarter worth about $122,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Keros Therapeutics during the first quarter worth about $129,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on KROS. Wells Fargo & Company decreased their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 5th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Finally, Leerink Partners decreased their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Keros Therapeutics currently has an average rating of “Hold” and a consensus target price of $20.50.

Insiders Place Their Bets

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the transaction, the insider directly owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This trade represents a 11.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 5,343 shares of company stock valued at $54,985. 12.60% of the stock is currently owned by corporate insiders.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $11.17 on Friday. The business’s 50-day simple moving average is $10.83 and its two-hundred day simple moving average is $11.22. The company has a market cap of $221.50 million, a PE ratio of -3.02 and a beta of 1.01. Keros Therapeutics, Inc. has a fifty-two week low of $9.69 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, analysts predict that Keros Therapeutics, Inc. will post -5.27 EPS for the current fiscal year.

Keros Therapeutics announced that its board has approved a stock repurchase plan on Wednesday, September 9th that allows the company to repurchase $5.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 2.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.